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Abstract
Background: Pleural effusions are classified into transudates and exudates. Various criteria have
been used with Light's et al being the most accepted ones. Glycosaminoglycans (GAGs) have been
detected during pleural fluids (PF) analysis in various causes. In this pilot study, we investigated: (a)
the usefulness of GAGs in the assessment of pleural effusions, and (b) whether and in what way
GAGs correlate with established criteria used to indicate an exudate.
Methods: LDH, total protein, cholesterol and GAG levels were measured in pleural fluid and
serum from 50 patients with pleural effusion. GAG levels were defined by the photometric method
of Hata. The discriminative properties of pleural GAGs (pGAG), pleural fluid/serum GAG ratio
(GAGR), serum GAGs (sGAG) and serum LDH (sLDH) were explored with ROC analysis.
Results:  According to ROC analysis, pGAG and GAGR exhibited satisfactory discriminative
properties in the separation of pleural effusions. For GAGR, at a 1.1 cut off point, sensitivity and
specificity reached 75.6%; 95%CI: 60.5–87.1 and 100%; 95%CI: 47.8–100, respectively. For pGAG
at a cut off value of 8.4 μg/ml, these percentages changed to 86.7%; 95%CI: 73.2–94.9 and 100%;
95%CI: 47.8–100. The study also revealed the differential role of sGAG between malignancies and
benign cases, scoring 68.8%; 95%CI: 50.0–83.9 for sensitivity, and 84.6%; 95%CI: 54.5–97.6 for
specificity at a 7.8 μg/ml cut off.
Conclusion: Our results suggest that glycosaminoglycan measurement of both serum and pleural
effusions could be useful for simultaneous differentiation of exudates from transudates, and of
malignant from benign exudates.
Background
Pleural effusions, being a common medical problem,
have been classically divided into transudates and exu-
dates. Differentiation is of particular importance because
in the case of a transudate, aetiology and therapy are
directed to the underlying congestive heart failure, cirrho-
sis, or nephrosis. Alternatively, if the effusion proves to be
an exudate, malignancy is suspected and a more extensive
diagnostic procedure is needed. According to Light's crite-
ria [1,2] which still remain the most accurate ones, pleural
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fluid is an exudate if any of the following are met: (a)
pleural fluid to serum ratio of total protein > 0.5, (b) pleu-
ral fluid to serum ratio of lactic acid dehydrogenase
(LDH) > 0.6, and (c) pleural fluid LDH > 3/4 the upper
limit of normal serum LDH. Additional criteria-such as
pleural fluid cholesterol level > 60 mg/dL or > 45 mg/d
[3,4], and a serum fluid albumin gradient > 1.2 mg/dl [5]
– have been also proposed in parallel or in combination
with Light to optimize sensitivity and specificity of diag-
nosis. Criteria, however, regarding the differentiation
between malignant and benign exudates have not been
yet established.
Glycosaminoglycans (GAGs) are long, straight chain
polysaccharides composed of repeated disaccharide units
that are mainly attached to a core protein to form prote-
oglycans. GAGs are subdivided into the chondroitin sul-
fates (chondroitin-4-sulfate and chondroitin-6-sulfate),
heparan sulfates (heparan sulfate and heparin), dermatan
sulfate, keratan sulfate and hyaluronic acid and their pres-
ence has been studied in several deceases. They are nor-
mally produced by the mesothelial cells of pleural cavity
and large amounts of them, mainly hyaluronic acid and
chondroitin sulphate [6,7] have already been reported in
pleural effusions. Afify et al [8] concluded that hyaluro-
nan and its cell surface receptor CD44v6 can serve as an
ancillary test to cytological examination, to distinguish
between malignant and benign effusions. Welker et al [9]
studied the combined use of cytology and hyaluronic acid
analysis in improving the detection of malignant mes-
othelioma in pleural effusions, reporting impressive
results.
In this pilot study we investigated: (a) the usefulness of
GAGs in the assessment of pleural effusions, and (b)
whether and in what way GAGs correlate with established
criteria used to indicate an exudate.
Methods
Patients
All the patients of the study were referred to the Respira-
tory Unit at 'Sotiria' General Hospital, Athens, Greece, for
a prospective investigation and removal of pleural effu-
sion. None of the patients followed previous diuretic diet.
During the study period, pleural effusion samples from 50
patients were collected, 29 men and 21 women, mean age
65.4 ± 15.9 years. Pleural fluid and serum samples were
collected from all patients centrifuged and kept at -70°C
immediately. All patients were followed for at least 3
months, or until a final cause of the pleural fluid was
determined (Table 1). Effusions were determined as exu-
dates or transudates according to the criteria of Light.
Malignancies were established by positive cytology in
combination with pleural fluid differential cell counts
and immunocytochemistry techniques when needed.
Pleural fluid positive cell cultures followed by positive
stains verified tuberculosis and parapneumonic effusions.
Amylase measurement was requested to confirm pancrea-
titis. All transudates were diagnosed as cardiac failures.
Evaluation was based on standard clinical procedures
(NYHA stage 3 and 4 and/or cardiography injection frac-
tion < 30). Thoracoscopy and pleural biopsy were per-
formed in cases of undiagnosed exudates. The study was
conducted in accordance with the ethical principles set
forth in the Declaration of Helsinki and with local regula-
tions. The protocol was approved by the Institutional Eth-
ics Committee of the School of Medicine, University of
Athens, reference number 1575/96.
Glycosaminoglycan measurement
All samples were analysed for GAGs according to Hata et
al [10]. Briefly, 1 ml of each sample was dehydrated by
adding 10 ml chilled acetone. The mixture was stirred for
30 min at room temperature and centrifuged at 1500 rpm
for 15 min at 4°C. The dehydrated sample was delipi-
dated by washing twice with 10 ml of ether and the pre-
cipitate was air-dried. The defatted dry powder was
resuspended in 1 ml of 0.5 M chilled NaOH and stirred at
4°C overnight. Then it was neutralised with 1 M HCl to
pH 6–8, an equal volume of 0.1 M Tris-HCl buffer was
added and the sample was heated for 30 min in a boiling
bath. The sample solution was digested with pronase E in
two doses of 1 mg at 24 h intervals, at 50°C. After being
acidified with 1 M HCl to pH 5–6, 2 ml cetylpyridinium
chloride (CPC) were added and kept at 4°C overnight.
The precipitate was collected by centrifugation at 4,000
rpm for 30 min at 4°C and then washed twice with 5 ml
of 98% ethanol containing 10% CH3COOK. The final
precipitate was dissolved in 1 ml of 0.05 Tris-HCl buffer.
Uronic acid was measured using the uronic acid-carbazole
reaction and GAGs were expressed as μg uronic acid per
ml of pleural fluid or serum [11]. Chemicals were pur-
chased by Sigma (S. Louis, Missouri).
Table 1: Clinical diagnosis of patients' pleural effusions.
Diagnosis n
Exudates (n = 45)
Malignancies 32
Parapneumonic 1
Tuberculosis 1
Pleuritis 4
Miscellaneous* 7
Transudates (n = 5)
Cardiac failure 5
Total 50
* Polyartiritis nodosa 1, collagenous disease 1, pancreatitis 1, post-
traumatic pleuritis 1, eosinophilic pleuritis 2, acute myelogenic 
leukaemia 1.BMC Pulmonary Medicine 2009, 9:9 http://www.biomedcentral.com/1471-2466/9/9
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Measurement of biochemical markers
Adequate amounts of the samples were kept to analyze for
glucose, total protein, LDH, cholesterol (CHOL) and trig-
lycerides (TGs) in pleural effusions and sera. All measure-
ments were performed in Olympus AU-640 analyser
(Medicon), at the biochemistry laboratory of the 'Sotiria'
General Hospital.
Statistical analysis
Analysis of results was performed with two statistical
packages: the SPSS 10 and the MedCalc software. Medians
with the first and third quartiles were calculated for over-
all nine parameters in all four study groups, i.e. transu-
dates, exudates, malignancies and benign cases. Because
most variables were not normally distributed, variables
were compared by means of non-parametric tests. Differ-
ences among the three groups (malignancies, benign and
transudates) were assessed with the Kruskal Wallis equal-
ity of populations rank test for three independent sam-
ples, followed by the Wilcoxon rank-sum (Mann-
Whitney) test. Correlations were performed with Spear-
man's rank order coefficient. The discriminative proper-
ties of pGAG, GAGR, sGAG and serum LDH (sLDH) were
explored with ROC analysis. All p-values < 0.05 were con-
sidered statistically significant.
Results
Malignancies vs. benign vs. transudates
Patients were classified into three groups. Group A
included 32 patients with malignant pleural effusions.
Group B consisted of 13 patients with benign disease, and
group C included 5 transudate effusions. Medians with
the first and third quartiles for each of the nine parameters
analyzed in the three studied groups are shown in Table 2.
All other parameters except sGAG, sTP and sLDH were sig-
nificantly higher in malignancies and benign disease than
transudate effusions. sGAG and sLDH were both signifi-
cantly increased in malignancies compared to benign
cases (p = 0.002, and p = 0.021, respectively).
We further assessed sGAG and sLDH as discriminative
markers in malignant vs. benign disease. The best cut off
points was selected using ROC analysis. With a 7.8 μg/ml
cut off value, sGAG showed sensitivity 68.7%; 95%C.I:
50.0–83.9 and specificity 84.6%; 95%C.I: 54.5–97.6. For
sLDH and a 201 u/l cut off, these percentages scored
Table 2: Medians with the first and third quartiles in parentheses and ranges in brackets of the nine parameters, in the malignant (A), 
benign (B) and transudates (C) group, respectively.
malignant (A), (n = 32) benign (B), (n = 13) transudates (C), (n = 5) Ptotal P
pGAG 14.0 (11.0–20.7), [4.0–52.6] 15.9 (9.3–23.7), [5.9–59.7] 4.9 (3.9–7.2), [3.3–8.4] 0.004 AvsB p = 0.582; AvsC p < 0.001; BvsC 
p = 0.001
sGAG 8.7 (7.2–11.2), [2.3–23.0] 6.6 (5.1–7.7), [3.3–9.9] 8.6 (6.6–13.0), [5.5–16.4] 0.007 AvsB p = 0.002; AvsC p = 0.983; BvsC 
p = 0.059
GAGR 1.7 (1.1–2.5), [0.5–4.3] 2.3 (1.3–5.0), [0.9–8.6] 0.5 (0.3–1.1), [0.3–1.1] 0.003 AvsB p = 0.059; AvsC p = 0.004; BvsC 
p = 0.001
pTP 4.2 (3.4–5.2), [1.6–6.1] 4.3 (3.6–4.8), [3.0–5.2] 2.6 (2.1–2.7), [1.6–2.8] 0.003 AvsB p = 0.930; AvsC p = 0.001; BvsC 
p < 0.001
sTP 6.3 (5.7–7.2), [4.7–8.6] 6.6 (6.1–7.1), [5.3–7.9] 6.3 (5.0–6.7), [4.8–7.0] 0.444 AvsB p = 0.607; AvsC p = 0.350; BvsC 
p = 0.173
TPR 0.6 (0.6–0.7), [0.3–2.0] 0.6 (0.6–0.7), [0.5–2.0] 0.4 (0.3–0.5), [0.2–0.5] 0.009 AvsB p = 0.920; AvsC p = 0.002; BvsC 
p = 0.001
pLDH 333.5 (207.0–666.2), [74–
7000]
242.0 (144.0–521.0), [73–
677]
103.0 (66.5–144.5), [63–
177]
0.004 AvsB p = 0.215; AvsC p < 0.001; BvsC 
p = 0.014
sLDH 256.0 (204.2–366.0), [163–
1018]
201.0 (165.5–253.0), [129–
309]
262.0 (237.0–267.5), [214–
272]
0.056 AvsB p = 0.210; AvsC p = 0.914; BvsC 
p = 0.117
LDHR 1.2 (0.8–1.8), [0.3–9.5] 1.4 (0.6–2.8), [0.4–3.2] 0.4 (0.3–1.00), [0.2–0.7] 0.008 AvsB p = 0.773; AvsC p = 0.001; BvsC 
p = 0.004
Column 4 presents total scores of p-values as these were formulated by the Kruskal-Wallis rank test. Differences among pairs are included in the 
last column.BMC Pulmonary Medicine 2009, 9:9 http://www.biomedcentral.com/1471-2466/9/9
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81.2%; 95%C.I: 63.6–92.7 and 53.8%; 95%C.I: 25.2–
80.7, respectively (Table 3).
Exudates vs. transudates
Differences among transudates vs. all exudates, number-
ing 5 and 45 patients respectively, were also studied. Pleu-
ral fluid GAGs (pGAG) and the pleural fluid/serum GAG
ratio (GAGR) were both significantly higher (p < 0.001, p
= 0.001) in the exudate group (Table 4). This was also
observed with pleural fluid total protein, pLDH, and
LDHR (p < 0.001 for all three parameters). No statistical
difference was found in serum GAGs (sGAG); on the con-
trary values were very close. According to ROC analysis,
both GAGR and pGAG exhibited satisfactory discrimina-
tive properties. The 1.1 cut off value demonstrated the
highest accuracy for GAGR (sensitivity 75.6%; 95%CI:
60.5–87.1; specificity 100%; 95%CI: 47.8–100), whereas
a cut off point of 8.4 μg/ml yielded optimum results for
pGAG (sensitivity 86.7%; 95%CI: 73.2–94.9; specificity
100%; 95%CI: 47.8–100). Sensitivities and specificities of
Light's criteria were also estimated (Table 5).
Correlations
In the total group of 50 patients, GAGR correlated signifi-
cantly with TPR (r = 0.414, p = 0.003, Figure 1), and
LDHR (r = 0.520, p < 0.0001, Figure 2). pGAG levels
exhibited a mild positive correlation with total pleural
protein (r = 0.287, p = 0.043, Figure 3), and a strong pos-
itive correlation with pLDH (r = 0.627, p < 0.0001, Figure
4). sGAG and sLDH were also positively correlated (r =
0.430, p = 0.002, Figure 5). No statistically significant cor-
relation was observed between total serum protein with
either sGAG, or sLDH.
Discussion
This study investigates the discriminative role of gly-
cosaminoglycans between (a) exudates and transudates,
and (b) malignant and benign exudates, using ROC anal-
ysis. The statistically significant raise of pGAG in the exu-
date group indicate the possible existence of pathological
processes that result in either increased permeability, local
production or decreased clearance of the pleural gly-
cosaminoglycans similar to those governing the protein
and LDH content. This suggestion is further supported by
Table 4: Medians with the first and third quartiles in parentheses, and ranges in brackets, of the nine parameters, in the exudate and 
transudate group, respectively.
Exudates (n = 45) Transudates (n = 5) p
pGAG 14.4 (10.4–21.3), [4.0–59.7] 4.9 (3.9–7.2), [3.3–8.4] < 0.001
sGAG 8.0 (6.6–9.8), [2.3–23.0] 8.6 (6.6–13.0), [5.5–16.4] 0.571
GAGR 1.9 (1.1–2.9), [0.5–8.6] 0.5 (0.3–1.1), [0.3–1.1] 0.001
pTP 4.2 (3.4–5.0), [1.6–6.1] 2.6 (2.1–2.7), [1.6–2.8] < 0.001
sTP 6.5 (5.8–7.1), [4.7–8.6] 6.3 (5.0–6.7), [4.8–7.0] 0.267
TPR 0.6 (0.6–0.7), [0.3–2.0] 0.4 (0.3–0.5), [0.2–0.5] 0.001
pLDH 331.0 (195.0–596.0), [73–7000] 103.0 (66.5–144.5), [63–177] < 0.001
sLDH 225.0 (200.5–324.5), [129–1018] 262.0 (237.0–267.5), [214–272] 0.550
LDHR 1.3 (0.7–2.0), [0.3–9.5] 0.4 (0.3–1.0), [0.2–0.7] < 0.001
For each parameter, comparisons between the two groups were made to establish statistically significant differences.
Table 3: Sensitivity, specificity, and 95% CI, for the cut off values of sGAG and sLDH obtained with ROC analysis, between malignant 
and benign exudates.
Cut off point Sensitivity (%) 95% CI Specificity (%) 95% CI
sGAG 7.8 μg/ml 68.7 50.0–83.9 84.6 54.5–97.6
sLDH 201 u/l 81.2 63.6–92.7 53.8 25.2–80.7BMC Pulmonary Medicine 2009, 9:9 http://www.biomedcentral.com/1471-2466/9/9
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the fact that GAGR correlate with TPR and LDHR, while
pGAG correlate with total pleural protein and pLDH.
Interestingly, pGAG levels showed no difference between
malignant and benign cases, with sGAG, however, show-
ing a significant increase in malignancies.
Since 1972, when Light first published his criteria for the
differentiation of pleural effusions, additional markers
have been proposed. Cholesterol, bilirubin and albumin
gradient have been extensively studied. According to a
meta-analysis by Heffner et al [12], the most frequently
used markers, except bilirubin, perform well, although the
protein ratio appears marginally the best. In our study,
both pGAG and GAGR exhibited interesting discriminat-
ing properties regarding transudates vs. exudates, with
pGAG giving slightly higher sensitivity scores. Although
the number of patients in the transudate group was very
small (n = 5), both GAGR and pGAG correctly detected
them all, maximizing specificity, while pGAG misclassi-
fied 6 out of the 45 exudates. GAGR, however, exhibited
the poorest sensitivity over the other four parameters
(Table 4). TPR correctly classified 42 of the 45 exudates,
giving the highest sensitivity (93.3%), but in expense of
specificity (60%). LDH and pGAG performed best com-
pared to the other criteria. Among benign vs. malignant
cases, sGAG was the marker with relatively good sensitiv-
ity and specificity scores. sLDH -a parameter classically
pGAR levels are positively correlated with total pleural pro- tein Figure 3
pGAR levels are positively correlated with total pleu-
ral protein.
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Table 5: Sensitivity, specificity, and 95% CI, for the cut off values of TPR, LDHR, LDH, GAGR, and pGAG, obtained by ROC analysis 
between exudate and transudate effusions.
Cut off point Sensitivity (%) 95% CI Specificity (%) 95% CI
TPR 0.5 93.9 81.7–98.6 60.0 14.7–94.7
LDHR 0.6 84.4 70.5–93.5 80.0 28.4–99.5
LDH 250 u/l 88.9 75.9–96.3 80.0 28.4–99.5
GAGR 1.1 75.6 60.5–87.1 100 47.8–100
pGAG 8.4 μg/ml 86.7 73.2–94.9 100 47.8–100
GAGR is positively correlated with TPR Figure 1
GAGR is positively correlated with TPR.
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used in Light's criteria-, gave a higher sensitivity percent-
age compared to sGAG, followed however by a low specif-
icity one (Table 5).
Because what causes a transudate is usually easily
detected, researchers have been mainly focused on the
diagnosis of exudates. Especially, the establishment of
malignant effusions continues to be a clinical problem as
its final diagnosis depends heavily on cytological exami-
nation, a technique with low sensitivity scores. However,
in every day clinical practice transudates are more com-
mon and if the cause is not that clear they as well call for
a precise and reliable diagnosis. A marker that would
direct initial clinical judgment on either transudates or
malignancies could be a valuable aid. Though our study is
limited by the small sample size and the re-testing of reli-
ability in the same sample, findings indicate that GAGs
could be possible candidates for such a role under the
condition that results are further tested and justified over
a much larger number of patients.
Conclusion
Although many studies appear in the literature to investi-
gate the significance of glycosaminoglycans' presence in
pleural effusions, only few studies have been concentrated
in the identification of markers that can differentiate
between malignant and benign disease. The fact that both
benign and malignant effusions share the same lym-
phocytic exudative profile makes it difficult to determine
a specific diagnosis and the need for establishing specific
criteria is growing. Investigations include markers such as
hyaluronan, interleukin-6, tumor necrosis factor, and C-
reactive protein. Bernard et al [13] also proposed the use
of F-FDG PET imaging for the differentiation between
benign and malignant exudates, succeeding impressive
results. Our results suggest that glycosaminoglycan meas-
urement of both serum and pleural effusions could be
useful for simultaneous differentiation of exudates from
transudates and of malignant from benign exudates.
These findings guarantee the need for further investiga-
tion.
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